In The News

Antidepressant Medication Use and Glycemic Control in Co-Morbid Type 2 Diabetes and Depression

January 7, 2016. Depression is highly prevalent in patients with diabetes and is associated with multiple negative outcomes. This retrospective cohort study (n=1399) evaluated patients with concurrent type 2 diabetes and depression who attended ambulatory primary care visits to assess whether the use of antidepressant medications was associated with good glycemic control (defined as A1C

American Association of Clinical Endocrinologists/American College of Endocrinology Release 2016 Comprehensive Type 2 Diabetes Management Algorithm

January 5, 2016. The American Association of Clinical Endocrinologists (AACE), in conjunction with the American College of Endocrinology (ACE), has announced the publication of its 2016 update of the AACE/ACE Comprehensive Diabetes Management Algorithm and Executive Summary as a clinical guide for physicians managing the care of patients with type 2 diabetes. The 2016 algorithm considers new therapies, disease management approaches, and key clinical data.

Do Patients With Newly Diagnosed Diabetes Benefit From Early Specialist Care?

January 2016. This large, population-based, propensity score-matched cohort study used administrative health data from Ontario, Canada (1998-2006, N=79,020) to evaluate cardiovascular (CV) mortality and events in patients who received endocrinologist care in the year following diabetes diagnosis, compared with patients who received primary care alone.

Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes

December 17, 2015. This randomized, crossover, noninferiority study found that intranasal glucagon was highly effective at treating insulin-induced hypoglycemia. Patients from 8 clinical centers (N=75) were evaluated following receipt of intranasal glucagon (3 mg) or intramuscular glucagon (1 mg). Success was defined as achieving glucose levels ≥70 mg/dL or ≥20 mg/dL from the glucose low point within 30 minutes of glucagon administration. Success rates (and mean time to success) with intranasal and intramuscular glucagon, respectively were 98.7% (16 minutes) and 100% (13 minutes).

FDA Approves Basaglar, the First “Follow-on” Insulin Glargine Product to Treat Diabetes

December 16, 2015. The US Food and Drug Administration (FDA) has approved insulin Basaglar (insulin glargine injection), the first insulin product approved through an abbreviated approval pathway. This application relied, in part, on the FDA’s finding of safety and effectiveness for Lantus (insulin glargine injection).

AHA Scientific Statement: Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus

December 7, 2015. The American Heart Association (AHA) has released a scientific statement on the cardiovascular consequences of diabetes, based on gender. According to the AHA, having type 2 diabetes places women at greater cardiovascular risk than men. The comprehensive statement evaluates the available evidence base and suggests areas for further research. You can download the document here.

Insulin Degludec Does Not Increase Antibody Formation Versus Insulin Glargine: An Evaluation of Phase 3a Trials

December 2015. This study evaluated insulin antibody formation in patients with type 1 and type 2 diabetes (T1D/T2D) treated with once-daily insulins degludec (IDeg) or glargine (IGlar). Insulin antibodies were measured using subtraction radio-immunoassay data from 6 phase 3a clinical trials. Investigators found that IDeg- and IGlar-specific antibodies remained low (<1% bound/total radioactivity [%B/T]), with low levels of antibodies cross-reacting with human insulin in patients with T1D (<20%B/T) and T2D (<6%B/T).

FDA Drug Safety Communication: SGLT2 Inhibitor Labels to Include Warnings About Too Much Acid in the Blood and Serious Urinary Tract Infections

December 4, 2015. A US Food and Drug Administration (FDA) safety review has resulted in warnings being added to the labels of the sodium-glucose cotransporter-2 (SGLT2) inhibitor class medicines used in type 2 diabetes. These warnings update an earlier May 2015 communication and relate to the risk of too much acid in the blood and of serious urinary tract infections (UTIs) in patients using SGLT2 inhibitors.

Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus

November 18, 2015. This analysis evaluated data from 9 randomized controlled trials (N=10,194) of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin (100 mg and 300 mg doses) to assess the effects of this drug on bone fracture risk in patients with type 2 diabetes. Investigators found a higher risk of fracture in patients taking canagliflozin.